Venter, Willem Daniel FrancoisGandhi, MonicaSokhela, SimisoSikwese, KenlyBygrave, HelenDa Gama, LouisMphothulo, NdiviweJamieson, LiseSiedner, Mark J.Pozniak, Anton L.Rojo, PabloBaptiste, Solange L.Wambui, JacqueMeyer-Rath, GesineHonermann, BrianWarren, MitchellBekker, Linda-GailSinxadi, PhumlaCollins, SimonBurry, JessicaMoller, KarlienClayden, PollyOwen, AndrewHill, Andrew2025-05-142024-10Venter, W.D.F., Gandhi, M., Sokhela, S. et al. 2024, 'The long wait for long-acting HIV prevention and treatment formulations', Lancet HIV, vol. 11, no. 10, pp. e711-e716, doi : 10.1016/S2352-3018(24)00173-5.2405-4704 (print)2352-3018 (online)10.1016/S2352-3018(24)00173-5http://hdl.handle.net/2263/102390Large randomised studies of new long-acting medications for the prevention and treatment of HIV have shown high effectiveness and acceptability. Although modelling studies indicate these agents could be fundamental in HIV elimination, coordination of their entry into health-care markets is crucial, especially in low-income and middle-income countries with high HIV prevalence, where coordination is low despite UNAIDS flagging that global HIV targets will not be met. Research and implementation projects are tightly controlled by originator pharmaceutical companies, with only a small percentage of eligible people living with or affected by HIV benefiting from these projects. WHO, financial donors, manufacturers, and governments need to consider urgent coordinated action from stakeholders worldwide, akin to the successful introduction of dolutegravir into treatment programmes across low-income and middle-income countries. Without this immediate coordination, large-scale access to long-acting agents for HIV will be delayed, potentially extending into the 2030s. This delay is unacceptable considering the established global HIV targets.en© 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Notice : this is the author’s version of a work that was accepted for publication in Lancet HIV. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in Lancet HIV, vol. 11, no. 10, pp. e711-e716, doi : 10.1016/S2352-3018(24)00173-5.Human immunodeficiency virus (HIV)PreventionTreatmentViewpointPostprint Article